Healthcare investors were presented with major movements in two small stocks today: Amicus Therapeutics (NASDAQ:FOLD) popped almost 21% on strong phase 3 data for a Fabry disease drug, while Biota Pharmaceuticals (NASDAQ:BOTA) collapsed 34% upon receiving a stop-work order from the Biomedical Advanced Research and Development Authority (BARDA). While a single government contract for developing influenza vaccines may not sound like a huge potential issue for a company, the contract in question has generated the majority of Biota's revenue since the company won the contract in 2011.

Check out the video below for more information on the two stocks and how investors may want to respond to these major movers.

David WilliamsonMichael Douglass, and The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.